On January 11, the Centers for Medicare and Medicaid Services announced a proposal to cover Food and Drug Administration-approved monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s disease, including aducanumab, under Coverage with Evidence Development (CED) in CMS-approved randomized controlled trials.
American Geriatrics Society expresses misgivings about FDA-approved Alheimer’s drug
